Genenta Science S.P.A. (GNTA) — SEC Filings
Genenta Science S.P.A. (GNTA) — 22 SEC filings. Latest: 6-K (Mar 27, 2026). Includes 18 6-K, 2 20-F, 1 20-F/A.
View Genenta Science S.P.A. on SEC EDGAR
Overview
Genenta Science S.P.A. (GNTA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 27, 2026: Genenta Science S.p.A. filed a Form 6-K on March 27, 2026. This report is for a foreign issuer and includes various documents such as the 6-K form itself, an exhibit EX-10.1, and an exhibit EX-99.1, along with a graphic file. The company's mailing and business address are both listed as OLGETTINA, N
Sentiment Summary
Across 22 filings, the sentiment breakdown is: 1 bullish, 20 neutral, 1 mixed. The dominant filing sentiment for Genenta Science S.P.A. is neutral.
Filing Type Overview
Genenta Science S.P.A. (GNTA) has filed 18 6-K, 2 20-F, 1 20-F/A, 1 SC 13G/A with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (22)
Risk Profile
Risk Assessment: Of GNTA's 22 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Carlo Russo, MD
- Pierluigi Paracchi
Industry Context
Genenta Science S.p.A. operates in the biotechnology sector, focusing on the development of novel therapies.
Top Tags
sec-filing (8) · registration-statement (5) · biotech (4) · amendment (4) · shareholder-meeting (3) · corporate-governance (3) · filing (3) · financing (2) · 6-k (2) · Genenta Science (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Gross Proceeds | $10.0M | Funds raised from the registered direct offering to support operations and clinical trials. |
| Period of Report | 20250630 | The financial and operational data pertains to this date. |
| Filing Date | 20251010 | The date the report was submitted to the SEC. |
| Reporting Period End Date | 2024-12-31 | Indicates the end of the fiscal year for which financial information is reported. |
| Financing | €20 million | Total potential funding from ETB |
| SEC File Number | 001-41115 | Identifies the company's filing history with the SEC. |
| Ordinary Shares Outstanding | 18,216,958 | As of December 31, 2023 |
| Fiscal Year End | 2023-12-31 | Period covered by the annual report |
| Conformed Period of Report | 2023-12-31 | Fiscal year end date |
| Filed as of Date | 2024-03-29 | Date the report was filed |
| Date of Name Change | 2021-01-04 | Effective date of former name change |
| Standard Industrial Classification | 2836 | Industry code for Biological Products |
| Ordinary Shares | 2,294,421 | Number of shares beneficially owned by Pierluigi Paracchi in Genenta Science S.p.A. as of December 31, 2023. |
Forward-Looking Statements
- {"claim":"Pierluigi Paracchi will maintain a significant ownership stake in Genenta Science S.p.A. for the foreseeable future.","entity":"Pierluigi Paracchi","targetDate":"December 31, 2024","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Genenta Science S.P.A. (GNTA)?
Genenta Science S.P.A. has 22 recent SEC filings from Feb 2024 to Mar 2026, including 18 6-K, 2 20-F, 1 20-F/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GNTA filings?
Across 22 filings, the sentiment breakdown is: 1 bullish, 20 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Genenta Science S.P.A. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Genenta Science S.P.A. (GNTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Genenta Science S.P.A.?
Financial highlights for Genenta Science S.P.A. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for GNTA?
The investment thesis for GNTA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Genenta Science S.P.A.?
Key executives identified across Genenta Science S.P.A.'s filings include Carlo Russo, MD, Pierluigi Paracchi.
What are the main risk factors for Genenta Science S.P.A. stock?
Of GNTA's 22 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Genenta Science S.P.A.?
Recent forward-looking statements from Genenta Science S.P.A. include guidance on {"claim":"Pierluigi Paracchi will maintain a significant ownership stake in Genenta Science S.p.A. for the foreseeable f.